Health Sector News: Key Developments and Industry Shifts
This summary covers critical developments in the health sector, including The Lancet's refusal to testify in the U.S. Senate's COVID origins inquiry, Purdue Pharma's opioid sentencing delay, and U.S. policy shifts on marijuana. It also highlights significant changes in pharmaceutical and insurance practices affecting patient treatments and regulatory actions.
The Lancet, a leading medical journal, has declined a U.S. Senate request to provide evidence in an inquiry into the origins of the COVID-19 pandemic, according to its editor-in-chief Richard Horton. The decision was made public during an interview at the Reuters Pharma event in Barcelona.
Purdue Pharma's criminal sentencing over opioid marketing has been delayed by a federal judge to allow for more public input. The case centers on Purdue's role in the opioid epidemic, with a potential $5.5 billion financial penalty that includes both fines and forfeiture.
In a major policy shift, the U.S. Department of Justice announced plans to ease restrictions on certain marijuana products and reclassify the drug as less dangerous. This move could significantly impact the $47 billion cannabis industry, which has been hindered by federal regulations despite widespread state-level legalization.
(With inputs from agencies.)
- READ MORE ON:
- health
- Lancet
- COVID-19
- Purdue Pharma
- opioid
- marijuana
- policy
- insurance
- pharmaceutical
- regulatory
ALSO READ
Health Headlines: COVID Inquiry, CBD Access, and Opioid Sentencing
Global Health News: Lancet's Senate Rejection, Opioid Crisis Developments, and Innovation in Medical Coverage
Ghana Mineworkers Union Protests Local Contractor Policy
The Opioid Settlement Maze: Navigating Purdue Pharma’s Compensation Challenges
Driving Towards a Greener Future: Delhi's Ambitious Electric Vehicle Policy 2026
Google News